TransCode Therapeutics ( ($RNAZ) ) has issued an update. On October 14, 2025, TransCode Therapeutics announced the completion of its Phase 1a ...

TransCode Therapeutics (NASDAQ:RNAZ) shares jumped 50% on Wednesday after the company announced the acquisition of Polynoma ...

Investing.com -- TransCode Therapeutics (NASDAQ:RNAZ) stock surged 50% after announcing the acquisition of Polynoma and a $25 ...

TransCode Therapeutics, Inc. (NASDAQ: RNAZ) announces completion of Phase 1a clinical trial with TTX-MC138, an investigational inhibitor of microRNA-10b, or miR-10b. By meeting its primary safety ...

"We are honored to welcome Dr. Zamore to our Science Advisory Board," said Dr. Zdravka Medarova, Chief Scientific Officer and co-founder of TransCode Therapeutics. "His deep expertise in RNA biology ...

Transcode Therapeutics shares are trading lower by 62% during Tuesday's session. The company announced pricing of its public offering. Our government trade tracker caught Pelosi’s 169% AI winner.

We have been fortunate to complete two financings in recent months. We believe that these two financings together have provided enough capital to support TTX-MC138's Phase I clinical trial and company ...

BOSTON, Nov. 05, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced that it ...

TransCode Therapeutics, Inc. (NASDAQ: RNAZ) ("TransCode or the "Company") announced today that it entered into a definitive agreement to acquire Polynoma LLC, a privately-held biotechnology ...

Upon completion of the transaction, CK Life will own about 9.1 per cent of TransCode's outstanding common shares ...